Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$14.38 USD

14.38
59,909

+0.25 (1.77%)

Updated Aug 19, 2026 04:00 PM ET

After-Market: $14.40 +0.02 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.22%
3Hold10.27%
4Sell5.79%
5Strong Sell3.20%
S&P50011.55%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (146 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Zacks Equity Research

Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.

Zacks Equity Research

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Zacks Equity Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

Zacks Equity Research

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

by Zacks Equity Research

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Zacks Equity Research

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Zacks Equity Research

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Zacks Equity Research

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Zacks Equity Research

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates

by Zacks Equity Research

Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.